{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,6,11]],"date-time":"2025-06-11T04:09:02Z","timestamp":1749614942198,"version":"3.41.0"},"reference-count":50,"publisher":"Gobierno de Navarra","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["An Sist Sanit Navar"],"published-print":{"date-parts":[[2018,4,30]]},"DOI":"10.23938\/assn.0121","type":"journal-article","created":{"date-parts":[[2018,1,23]],"date-time":"2018-01-23T09:50:21Z","timestamp":1516701021000},"page":"83-90","source":"Crossref","is-referenced-by-count":0,"title":["Past and present of monitoring the functional immune response developed against Epstein-Barr and Adenovirus in hematopoietic stem cell transplantation"],"prefix":"10.23938","volume":"41","member":"10024","reference":[{"key":"ref0","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1038\/sj.bmt.1705140","article-title":"Cause of death after allogeneic haematopoietic stem cell transplantation (HSCT) in early leukaemias: an EBMT analysis of lethal infectious complications and changes over calendar time","volume":"36","author":"GRATWOHL","year":"2005","unstructured":"GRATWOHL A, BRAND R, FRASSONI F, ROCHA V, NIEDERWIESER D, REUSSER P et al. Cause of death after allogeneic haematopoietic stem cell transplantation (HSCT) in early leukaemias: an EBMT analysis of lethal infectious complications and changes over calendar time. Bone Marrow Transplant 2005; 36: 757-769.","journal-title":"Bone Marrow Transplant"},{"key":"ref1","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1111\/imr.12138","article-title":"Antiviral T-cell therapy","volume":"258","author":"LEEN","year":"2014","unstructured":"2. LEEN AM, HESLOP HE, BRENNER MK. Antiviral T-cell therapy. Immunol Rev 2014; 258: 12-29.","journal-title":"Immunol Rev"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"925","DOI":"10.1182\/blood-2009-08-239186","article-title":"Long-term outcome of EBV-specific T-cell infusions to prevent or treat EBV-related lymphoproliferative disease in transplant recipients","volume":"115","author":"HESLOP","year":"2010","unstructured":"3. HESLOP HE, SLOBOD KS, PULE MA, HALE GA, ROUSSEAU A, SMITH CA et al. Long-term outcome of EBV-specific T-cell infusions to prevent or treat EBV-related lymphoproliferative disease in transplant recipients. Blood 2010; 115: 925-935.","journal-title":"Blood"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"1986","DOI":"10.1182\/blood-2014-06-573725","article-title":"Adoptive T-cell therapy with hexon-specific Th1 cells as a treatment of refractory adenovirus infection after HSCT","volume":"125","author":"FEUCHT","year":"2015","unstructured":"4. FEUCHT J, OPHERK K, LANG P, KAYSER S, HARTL L, BETHGE W et al. Adoptive T-cell therapy with hexon-specific Th1 cells as a treatment of refractory adenovirus infection after HSCT. Blood 2015; 125: 1986-1894.","journal-title":"Blood"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"13157","DOI":"10.1073\/pnas.1410785111","article-title":"RNA-guided endonuclease provides a therapeutic strategy to cure latent herpesviridae infection","volume":"111","author":"WANG","year":"2014","unstructured":"5. WANG J, QUAKE SR. RNA-guided endonuclease provides a therapeutic strategy to cure latent herpesviridae infection. Proc Natl Acad Sci U S A 2014; 111: 13157-13162.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1016\/j.stem.2015.03.011","article-title":"New cell sources for T cell engineering and adoptive immunotherapy","volume":"16","author":"THEMELI","year":"2015","unstructured":"6. THEMELI M, RIVI\u00c8RE I, SADELAIN M. New cell sources for T cell engineering and adoptive immunotherapy. Cell Stem Cell 2015; 16: 357-366.","journal-title":"Cell Stem Cell"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1182\/blood-2015-10-672345","article-title":"Unbalanced recovery of regulatory and effector T cells after allogeneic stem cell transplantation contributes to chronic GVHD","volume":"127","author":"ALHO","year":"2016","unstructured":"7. ALHO AC, KIM HT, CHAMMAS MJ, REYNOLDS CG, MATOS TR, FORCADE E et al. Unbalanced recovery of regulatory and effector T cells after allogeneic stem cell transplantation contributes to chronic GVHD. Blood 2016; 127: 646-657.","journal-title":"Blood"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"3861","DOI":"10.1182\/blood-2009-12-234096","article-title":"Immune reconstitution after allogeneic transplantation and expanding options for immunomodulation: an update","volume":"115","author":"SEGGEWISS","year":"2010","unstructured":"8. SEGGEWISS R, EINSELE H. Immune reconstitution after allogeneic transplantation and expanding options for immunomodulation: an update. Blood 2010; 115: 3861-3868.","journal-title":"Blood"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1038\/sj.bmt.1704966","article-title":"Immune restoration following hematopoietic stem cell transplantation: an evolving target","volume":"35","author":"JJ","year":"2005","unstructured":"9. AULETTA JJ, LAZARUS HM. Immune restoration following hematopoietic stem cell transplantation: an evolving target. Bone Marrow Transplant 2005; 35: 835-857.","journal-title":"Bone Marrow Transplant"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"114","DOI":"10.3324\/haematol.2014.113415","article-title":"Cytomegalovirus shapes long-term immune reconstitution after allogeneic stem cell transplantation","volume":"100","author":"ITZYKSON","year":"2015","unstructured":"10. ITZYKSON R, ROBIN M, MOINS-TEISSERENC H, DELORD M, BUSSON M, XHAARD A et al. Cytomegalovirus shapes long-term immune reconstitution after allogeneic stem cell transplantation. Haematologica 2015; 100: 114-123.","journal-title":"Haematologica"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"1600","DOI":"10.3324\/haematol.2012.072264","article-title":"T-cell reconstitution after allogeneic stem cell transplantation: assessment by measurement of the sjTREC\/\u03b2TREC ratio and thymic naive T cells","volume":"98","author":"RINGHOFFER","year":"2013","unstructured":"11. RINGHOFFER S, ROJEWSKI M, D\u00d6HNER H, BUNJES D, RINGHOFFER M. T-cell reconstitution after allogeneic stem cell transplantation: assessment by measurement of the sjTREC\/\u03b2TREC ratio and thymic naive T cells. Haematologica 2013; 98: 1600-1608.","journal-title":"Haematologica"},{"key":"ref11","doi-asserted-by":"publisher","unstructured":"12. BORCHERS S, BREMM M, LEHRNBECHER T, DAMMANN E, PABST B, W\u00d6LK B et al. Sequential anti-cytomegalovirus response monitoring may allow prediction of cytomegalovirus reactivation after allogeneic stem cell transplantation. PLoS One 2012; 7: e50248. doi: 10.1371\/journal.pone.0050248.","DOI":"10.1371\/journal.pone.0050248"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"40","DOI":"10.4049\/jimmunol.1601100","article-title":"Immune Reconstitution after Allogeneic Hematopoietic Stem Cell Transplantation: Time To T Up the Thymus","volume":"198","author":"CHAUDHRY","year":"2017","unstructured":"13. CHAUDHRY MS, VELARDI E, MALARD F, VAN DEN BRINK MR. Immune Reconstitution after Allogeneic Hematopoietic Stem Cell Transplantation: Time To T Up the Thymus. J Immunol 2017; 198: 40-46.","journal-title":"J Immunol"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"6477","DOI":"10.1182\/blood-2008-09-176594","article-title":"Acute graft-versus-host disease transiently impairs thymic output in young patients after allogeneic hematopoietic stem cell transplantation","volume":"113","author":"CLAVE","year":"2009","unstructured":"14. CLAVE E, BUSSON M, DOUAY C, PEFFAULT DE LATOUR R, BERROU J, RABIAN C et al. Acute graft-versus-host disease transiently impairs thymic output in young patients after allogeneic hematopoietic stem cell transplantation. Blood 2009; 113: 6477-6484.","journal-title":"Blood"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"901","DOI":"10.1080\/21505594.2016.1208866","article-title":"Immune reconstitution post allogeneic transplant and the impact of immune recovery on the risk of infection","volume":"7","author":"RS","year":"2016","unstructured":"15. MEHTA RS, REZVANI K. Immune reconstitution post allogeneic transplant and the impact of immune recovery on the risk of infection. Virulence 2016; 7: 901-916.","journal-title":"Virulence"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"784","DOI":"10.1002\/ajh.21227","article-title":"The influence of infection early after allogeneic stem cell transplantation on the risk of leukemic relapse and graft-versus-host disease","volume":"83","author":"KIM","year":"2008","unstructured":"16. KIM SY, LEE DG, KIM MS, KIM HJ, LEE S, MIN CK. The influence of infection early after allogeneic stem cell transplantation on the risk of leukemic relapse and graft-versus-host disease. Am J Hematol 2008; 83: 784-788.","journal-title":"Am J Hematol"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1002\/hon.2255","article-title":"Reduction of Foxp3+ T cell subsets involved in incidence of chronic graft-versus-host disease after allogeneic hematopoietic stem cell transplantation","volume":"35","author":"HU","year":"2017","unstructured":"17. HU Y, CUI Q, YE Y, LUO Y, TAN Y, SHI J et al. Reduction of Foxp3+ T cell subsets involved in incidence of chronic graft-versus-host disease after allogeneic hematopoietic stem cell transplantation. Hematol Oncol 2017; 35: 118-124.","journal-title":"Hematol Oncol"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1016\/j.bbmt.2010.04.011","article-title":"Recovery of CMV-specific CD8+ T cells and Tregs after allogeneic peripheral blood stem cell transplantation","volume":"17","author":"PASTORE","year":"2011","unstructured":"18. PASTORE D, DELIA M, MESTICE A, PERRONE T, CARLUCCIO P, GAUDIO F et al. Recovery of CMV-specific CD8+ T cells and Tregs after allogeneic peripheral blood stem cell transplantation. Biol Blood Marrow Transplant 2011; 17: 550-557.","journal-title":"Biol Blood Marrow Transplant"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"2215","DOI":"10.1158\/1078-0432.CCR-13-3205","article-title":"Ultra low-dose IL-2 for GVHD prophylaxis after allogeneic hematopoietic stem cell transplantation mediates expansion of regulatory T cells without diminishing antiviral and antileukemic activity","volume":"20","author":"KENNEDY-NASSER","year":"2014","unstructured":"19. KENNEDY-NASSER AA, KU S, CASTILLO-CARO P, HAZRAT Y, WU MF, LIU H et al. Ultra low-dose IL-2 for GVHD prophylaxis after allogeneic hematopoietic stem cell transplantation mediates expansion of regulatory T cells without diminishing antiviral and antileukemic activity. Clin Cancer Res 2014; 20: 2215-2225.","journal-title":"Clin Cancer Res"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"1503","DOI":"10.1182\/blood-2015-01-622837","article-title":"Acute GVHD results in a severe DC defect that prevents T-cell priming and leads to fulminant cytomegalovirus disease in mice","volume":"126","author":"WIKSTROM","year":"2015","unstructured":"20. WIKSTROM ME, FLEMING P, KUNS RD, SCHUSTER IS, VOIGT V, MILLER G et al. Acute GVHD results in a severe DC defect that prevents T-cell priming and leads to fulminant cytomegalovirus disease in mice. Blood 2015; 126: 1503-1514.","journal-title":"Blood"},{"key":"ref20","doi-asserted-by":"publisher","unstructured":"21. ULLAH MA, HILL GR, TEY SK. Functional Reconstitution of Natural Killer Cells in Allogeneic Hematopoietic Stem Cell Transplantation. Front Immunol 2016; 7: 144. doi: 10.3389\/fimmu.2016.00144.","DOI":"10.3389\/fimmu.2016.00144"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1038\/sj.leu.2405041","article-title":"Involvement of mature donor T cells in the NK cell reconstitution after haploidentical hematopoietic stem-cell transplantation","volume":"22","author":"NGUYEN","year":"2008","unstructured":"22. NGUYEN S, KUENTZ M, VERNANT JP, DHEDIN N, BORIES D, DEBR\u00c9 P et al. Involvement of mature donor T cells in the NK cell reconstitution after haploidentical hematopoietic stem-cell transplantation. Leukemia 2008; 22: 344-352.","journal-title":"Leukemia"},{"key":"ref22","doi-asserted-by":"publisher","unstructured":"23. HUENECKE S, CAPPEL C, ESSER R, PFIRRMANN V, SALZMANN-MANRIQUE E, BETZ S et al. Development of Three Different NK Cell Subpopulations during Immune Reconstitution after Pediatric Allogeneic Hematopoietic Stem Cell Transplantation: Prognostic Markers in GvHD and Viral Infections. Front Immunol 2017; 8: 109. doi: 10.3389\/fimmu.2017.00109.","DOI":"10.3389\/fimmu.2017.00109"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"3730","DOI":"10.1182\/blood-2002-08-2568","article-title":"Reconstitution of NK cell receptor repertoire following HLA-matched hematopoietic cell transplantation","volume":"101","author":"SHILLING","year":"2003","unstructured":"24. SHILLING HG, MCQUEEN KL, CHENG NW, SHIZURU JA, NEGRIN RS, PARHAM P. Reconstitution of NK cell receptor repertoire following HLA-matched hematopoietic cell transplantation. Blood 2003; 101: 3730-3740.","journal-title":"Blood"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1038\/sj.bmt.1705468","article-title":"Activating KIR genes are associated with CMV reactivation and survival after non-T-cell depleted HLA-identical sibling bone marrow transplantation for malignant disorders","volume":"38","author":"CHEN","year":"2006","unstructured":"25. CHEN C, BUSSON M, ROCHA V, APPERT ML, LEPAGE V, DULPHY N et al. Activating KIR genes are associated with CMV reactivation and survival after non-T-cell depleted HLA-identical sibling bone marrow transplantation for malignant disorders. Bone Marrow Transplant 2006; 38: 437-444.","journal-title":"Bone Marrow Transplant"},{"key":"ref25","doi-asserted-by":"publisher","unstructured":"26. SCHMID ET, PANG IK, CARRERA SILVA EA, BOSURGI L, MINER JJ, DIAMOND MS et al. AXL receptor tyrosine kinase is required for T cell priming and antiviral immunity. Elife 2016; 5. doi: 10.7554\/eLife.12414.","DOI":"10.7554\/eLife.12414"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"4002","DOI":"10.1182\/blood-2009-07-143545","article-title":"How I treat EBV lymphoproliferation","volume":"114","author":"HESLOP","year":"2009","unstructured":"27. HESLOP HE. How I treat EBV lymphoproliferation. Blood 2009; 114: 4002-4008.","journal-title":"Blood"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"346","DOI":"10.3324\/haematol.2013.087338","article-title":"Risk factors for Epstein-Barr virus-related post-transplant lymphoproliferative disease after allogeneic hematopoietic stem cell transplantation","volume":"99","author":"UHLIN","year":"2014","unstructured":"28. UHLIN M, WIKELL H, SUNDIN M, BLENNOW O, MAEURER M, RINGDEN O et al. Risk factors for Epstein-Barr virus-related post-transplant lymphoproliferative disease after allogeneic hematopoietic stem cell transplantation. Haematologica 2014; 99: 346-352.","journal-title":"Haematologica"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1097\/MOH.0000000000000083","article-title":"Epstein-Barr virus lymphoproliferative disease after hematopoietic stem cell transplant","volume":"21","author":"ROUCE","year":"2014","unstructured":"29. ROUCE RH, LOUIS CU, HESLOP HE. Epstein-Barr virus lymphoproliferative disease after hematopoietic stem cell transplant. Curr Opin Hematol 2014; 21: 476-481.","journal-title":"Curr Opin Hematol"},{"key":"ref29","doi-asserted-by":"publisher","first-page":"3979","DOI":"10.1182\/blood-2003-12-4287","article-title":"Prompt versus preemptive intervention for EBV lymphoproliferative disease","volume":"103","author":"WAGNER","year":"2004","unstructured":"30. WAGNER HJ, CHENG YC, HULS MH, GEE AP, KUEHNLE I, KRANCE RA et al. Prompt versus preemptive intervention for EBV lymphoproliferative disease. Blood 2004; 103: 3979-3981.","journal-title":"Blood"},{"key":"ref30","doi-asserted-by":"publisher","first-page":"803","DOI":"10.3324\/haematol.2016.144428","article-title":"Management of Epstein-Barr Virus infections and post-transplant lymphoproliferative disorders in patients after allogeneic hematopoietic stem cell transplantation: Sixth European Conference on Infections in Leukemia (ECIL-6) guidelines","volume":"101","author":"STYCZYNSKI","year":"2016","unstructured":"31. STYCZYNSKI J, VAN DER VELDEN W, FOX CP, ENGELHARD D, DE LA CAMARA R, CORDONNIER C et al. Management of Epstein-Barr Virus infections and post-transplant lymphoproliferative disorders in patients after allogeneic hematopoietic stem cell transplantation: Sixth European Conference on Infections in Leukemia (ECIL-6) guidelines. Haematologica 2016; 101: 803-811.","journal-title":"Haematologica"},{"key":"ref31","doi-asserted-by":"publisher","first-page":"2185","DOI":"10.1016\/j.bbmt.2015.07.035","article-title":"Epstein-Barr virus-related post-transplantation lymphoproliferative disorder after unmanipulated human leukocyte antigen haploidentical hematopoietic stem cell transplantation: incidence, risk factors, treatment, and clinical outcomes","volume":"21","author":"LP","year":"2015","unstructured":"32. XU LP, ZHANG CL, MO XD, ZHANG XH, CHEN H, HAN W et al. Epstein-Barr virus-related post-transplantation lymphoproliferative disorder after unmanipulated human leukocyte antigen haploidentical hematopoietic stem cell transplantation: incidence, risk factors, treatment, and clinical outcomes. Biol Blood Marrow Transplant 2015; 21: 2185-2191.","journal-title":"Biol Blood Marrow Transplant"},{"key":"ref32","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1038\/bmt.2016.238","article-title":"Association of Epstein-Barr virus reactivation with the recovery of CD4\/CD8 double-negative T lymphocytes after haploidentical hematopoietic stem cell transplantation","volume":"52","author":"BIAN","year":"2017","unstructured":"33. BIAN Z, LIU J, XU LP, CHANG YJ, WANG Y, ZHANG XH et al. Association of Epstein-Barr virus reactivation with the recovery of CD4\/CD8 double-negative T lymphocytes after haploidentical hematopoietic stem cell transplantation. Bone Marrow Transplant 2017; 52: 264-269.","journal-title":"Bone Marrow Transplant"},{"key":"ref33","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1200\/JCO.2011.39.8495","article-title":"Adoptive transfer of epstein-barr virus (EBV) nuclear antigen 1-specific t cells as treatment for EBV reactivation and lymphoproliferative disorders after allogeneic stem-cell transplantation","volume":"31","author":"ICHEVA","year":"2013","unstructured":"34. ICHEVA V, KAYSER S, WOLFF D, TUVE S, KYZIRAKOS C, BETHGE W et al. Adoptive transfer of epstein-barr virus (EBV) nuclear antigen 1-specific t cells as treatment for EBV reactivation and lymphoproliferative disorders after allogeneic stem-cell transplantation. J Clin Oncol 2013; 31: 39-48.","journal-title":"J Clin Oncol"},{"key":"ref34","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1016\/j.trim.2011.03.002","article-title":"The clinical value of concomitant Epstein Barr virus (EBV)-DNA load and specific immune reconstitution monitoring after allogeneic hematopoietic stem cell transplantation","volume":"24","author":"D'AVENI","year":"2011","unstructured":"35. D'AVENI M, A\u00cfSSI-ROTH\u00c9 L, VENARD V, SALMON A, FALENGA A, DECOT V et al. The clinical value of concomitant Epstein Barr virus (EBV)-DNA load and specific immune reconstitution monitoring after allogeneic hematopoietic stem cell transplantation. Transpl Immunol 2011; 24: 224-232.","journal-title":"Transpl Immunol"},{"key":"ref35","doi-asserted-by":"publisher","first-page":"1743","DOI":"10.1086\/503838","article-title":"Management of Epstein-Barr virus (EBV) reactivation after allogeneic stem cell transplantation by simultaneous analysis of EBV DNA load and EBV-specific T cell reconstitution","volume":"42","author":"ANNELS","year":"2006","unstructured":"36. ANNELS NE, KALPOE JS, BREDIUS RG, CLAAS EC, KROES AC, HISLOP AD et al. Management of Epstein-Barr virus (EBV) reactivation after allogeneic stem cell transplantation by simultaneous analysis of EBV DNA load and EBV-specific T cell reconstitution. Clin Infect Dis 2006; 42: 1743-1748.","journal-title":"Clin Infect Dis"},{"key":"ref36","doi-asserted-by":"publisher","first-page":"4290","DOI":"10.1182\/blood-2002-10-3001","article-title":"Impaired recovery of Epstein-Barr virus (EBV)--specific CD8+ T lymphocytes after partially T-depleted allogeneic stem cell transplantation may identify patients at very high risk for progressive EBV reactivation and lymphoproliferative disease","volume":"101","author":"MEIJ","year":"2003","unstructured":"37. MEIJ P, VAN ESSER JW, NIESTERS HG, VAN BAARLE D, MIEDEMA F, BLAKE N et al. Impaired recovery of Epstein-Barr virus (EBV)--specific CD8+ T lymphocytes after partially T-depleted allogeneic stem cell transplantation may identify patients at very high risk for progressive EBV reactivation and lymphoproliferative disease. Blood 2003; 101: 4290-4297.","journal-title":"Blood"},{"key":"ref37","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1111\/imm.12106","article-title":"Detection of Epstein-Barr virus-specific memory CD4+ T cells using a peptide-based cultured enzyme-linked immunospot assay","volume":"139","author":"CALAROTA","year":"2013","unstructured":"38. CALAROTA SA, CHIESA A, ZELINI P, COMOLLI G, MINOLI L, BALDANTI F. Detection of Epstein-Barr virus-specific memory CD4+ T cells using a peptide-based cultured enzyme-linked immunospot assay. Immunology 2013; 139: 533-544.","journal-title":"Immunology"},{"key":"ref38","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1086\/505498","article-title":"Adenovirus infections in transplant recipients","volume":"43","author":"ISON","year":"2006","unstructured":"39. ISON MG. Adenovirus infections in transplant recipients. Clin Infect Dis 2006; 43: 331-339.","journal-title":"Clin Infect Dis"},{"key":"ref39","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1111\/tid.12022","article-title":"European guidelines for diagnosis and treatment of adenovirus infection in leukemia and stem cell transplantation: summary of ECIL-4 (2011)","volume":"14","author":"MATTHES-MARTIN","year":"2012","unstructured":"40. MATTHES-MARTIN S, FEUCHTINGER T, SHAW PJ, ENGELHARD D, HIRSCH HH, CORDONNIER C et al. European guidelines for diagnosis and treatment of adenovirus infection in leukemia and stem cell transplantation: summary of ECIL-4 (2011). Transpl Infect Dis 2012; 14: 555-563.","journal-title":"Transpl Infect Dis"},{"key":"ref40","doi-asserted-by":"publisher","first-page":"1254","DOI":"10.3324\/haematol.11279","article-title":"Disseminated adenovirus infections after allogeneic hematopoietic stem cell transplantation: incidence, risk factors and outcome","volume":"92","author":"ROBIN","year":"2007","unstructured":"41. ROBIN M, MARQUE-JUILLET S, SCIEUX C, PEFFAULT DE LATOUR R, FERRY C, ROCHA V et al. Disseminated adenovirus infections after allogeneic hematopoietic stem cell transplantation: incidence, risk factors and outcome. Haematologica 2007; 92: 1254-1257.","journal-title":"Haematologica"},{"key":"ref41","doi-asserted-by":"publisher","first-page":"5476","DOI":"10.1182\/blood-2010-04-259291","article-title":"How I treat adenovirus in hematopoietic stem cell transplant recipients","volume":"116","author":"LINDEMANS","year":"2010","unstructured":"42. LINDEMANS CA, LEEN AM, BOELENS JJ. How I treat adenovirus in hematopoietic stem cell transplant recipients. Blood 2010; 116: 5476-5485.","journal-title":"Blood"},{"key":"ref42","doi-asserted-by":"publisher","first-page":"1619","DOI":"10.1182\/blood-2002-02-0377","article-title":"Adenovirus infections following allogeneic stem cell transplantation: incidence and outcome in relation to graft manipulation, immunosuppression, and immune recovery","volume":"100","author":"CHAKRABARTI","year":"2002","unstructured":"43. CHAKRABARTI S, MAUTNER V, OSMAN H, COLLINGHAM KE, FEGAN CD, KLAPPER PE et al. Adenovirus infections following allogeneic stem cell transplantation: incidence and outcome in relation to graft manipulation, immunosuppression, and immune recovery. Blood 2002; 100: 1619-1627.","journal-title":"Blood"},{"key":"ref43","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1038\/bmt.2012.221","article-title":"Impact of viral reactivations in the era of pre-emptive antiviral drug therapy following allogeneic haematopoietic SCT in paediatric recipients","volume":"48","author":"HIWARKAR","year":"2013","unstructured":"44. HIWARKAR P, GASPAR HB, GILMOUR K, JAGANI M, CHIESA R, BENNETT-REES N et al. Impact of viral reactivations in the era of pre-emptive antiviral drug therapy following allogeneic haematopoietic SCT in paediatric recipients. Bone Marrow Transplant 2013; 48: 803-808.","journal-title":"Bone Marrow Transplant"},{"key":"ref44","doi-asserted-by":"publisher","first-page":"1602","DOI":"10.1016\/j.bbmt.2011.08.014","article-title":"Dynamics of cytomegalovirus (CMV) plasma DNAemia in initial and recurrent episodes of active CMV infection in the allogeneic stem cell transplantation setting: implications for designing preemptive antiviral therapy strategies","volume":"17","author":"MU\u00d1OZ-COBO","year":"2011","unstructured":"45. MU\u00d1OZ-COBO B, SOLANO C, COSTA E, BRAVO D, CLARI M, BENET I et al. Dynamics of cytomegalovirus (CMV) plasma DNAemia in initial and recurrent episodes of active CMV infection in the allogeneic stem cell transplantation setting: implications for designing preemptive antiviral therapy strategies. Biol Blood Marrow Transplant 2011; 17: 1602-1611.","journal-title":"Biol Blood Marrow Transplant"},{"key":"ref45","doi-asserted-by":"publisher","first-page":"1290","DOI":"10.1086\/319984","article-title":"Treatment of adenovirus infections in patients undergoing allogeneic hematopoietic stem cell transplantation","volume":"32","author":"BORDIGONI","year":"2001","unstructured":"46. BORDIGONI P, CARRET AS, VENARD V, WITZ F, LE FAOU A. Treatment of adenovirus infections in patients undergoing allogeneic hematopoietic stem cell transplantation. Clin Infect Dis 2001; 32: 1290-1297.","journal-title":"Clin Infect Dis"},{"key":"ref46","doi-asserted-by":"publisher","first-page":"1943","DOI":"10.3324\/haematol.2010.022947","article-title":"Combined CD8+ and CD4+ adenovirus hexon-specific T cells associated with viral clearance after stem cell transplantation as treatment for adenovirus infection","volume":"95","author":"ZANDVLIET","year":"2010","unstructured":"47. ZANDVLIET ML, FALKENBURG JH, VAN LIEMPT E, VELTROP-DUITS LA, LANKESTER AC, KALPOE JS et al. Combined CD8+ and CD4+ adenovirus hexon-specific T cells associated with viral clearance after stem cell transplantation as treatment for adenovirus infection. Haematologica 2010; 95: 1943-1951.","journal-title":"Haematologica"},{"key":"ref47","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1111\/j.1365-2141.2004.05331.x","article-title":"Detection of adenovirus-specific T cells in children with adenovirus infection after allogeneic stem cell transplantation","volume":"128","author":"FEUCHTINGER","year":"2005","unstructured":"48. FEUCHTINGER T, L\u00dcCKE J, HAMPRECHT K, RICHARD C, HANDGRETINGER R, SCHUMM M et al. Detection of adenovirus-specific T cells in children with adenovirus infection after allogeneic stem cell transplantation. Br J Haematol 2005; 128: 503-509.","journal-title":"Br J Haematol"},{"key":"ref48","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1016\/j.bbmt.2010.09.010","article-title":"Quantitative and qualitative CD4 T cell immune responses related to adenovirus DNAemia in hematopoietic stem cell transplantation","volume":"17","author":"GU\u00c9RIN-EL KHOUROUJ","year":"2011","unstructured":"49. GU\u00c9RIN-EL KHOUROUJ V, DALLE JH, P\u00c9DRON B, YAKOUBEN K, BENSOUSSAN D, CORDEIRO DJ et al. Quantitative and qualitative CD4 T cell immune responses related to adenovirus DNAemia in hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2011; 17: 476-485.","journal-title":"Biol Blood Marrow Transplant"},{"key":"ref49","doi-asserted-by":"publisher","unstructured":"50. TISCHER S, GEYEREGGER R, KWOCZEK J, HEIM A, FIGUEIREDO C, BLASCZYK R et al. Discovery of immunodominant T-cell epitopes reveals penton protein as a second immunodominant target in human adenovirus infection. J Transl Med 2016; 14:286. doi: 10.1186\/s12967-016-1042-2.","DOI":"10.1186\/s12967-016-1042-2"}],"container-title":["Anales del Sistema Sanitario de Navarra"],"original-title":[],"link":[{"URL":"https:\/\/recyt.fecyt.es\/index.php\/ASSN\/article\/view\/58894\/39303","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,10]],"date-time":"2025-06-10T12:39:18Z","timestamp":1749559158000},"score":1,"resource":{"primary":{"URL":"https:\/\/recyt.fecyt.es\/index.php\/ASSN\/article\/view\/58894\/39303"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,4,30]]},"references-count":50,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,4]]}},"URL":"https:\/\/doi.org\/10.23938\/assn.0121","relation":{},"ISSN":["1137-6627"],"issn-type":[{"type":"print","value":"1137-6627"}],"subject":[],"published":{"date-parts":[[2018,4,30]]}}}